EV
Evoke Pharma, Inc.
EVOK · NASDAQ
$11.00 N/A (+$11.00)
Market Cap $18.9M
P/E Ratio -
Div. Yield -
ROE 101.40%
Bulios Fair Price
$7.13
35.2% downside
Current Price
$11
Undervalued Fair Value Overvalued
According to Bulios Fair Price, EVOK is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
63 /100
Fair P/B 5.64x
P/S 1.31x
P/FFO N/A
Growth
13 /100
Declining Book val. growth 2.30%
FCF growth N/A
EPS growth N/A
Profitability
20 /100
Weak Op. margin 35.99%
Gross margin 97.02%
FCF margin 23.05%
Quality
12 /100
Poor ROA 33.40%
ROIC 61.27%
Asset turnover 0.92x
Debt
46 /100
Moderate Int. coverage -9.45x
Debt/Equity 1.52x
Net debt/EBITDA 1.37x
Stability
31 /100
Unstable Profitable years 0
Beta -0.14x
EPS volatility 57.69%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about EVOK
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mark A. Kowieski
Employees
3
Headquarters
Solana Beach